reports
Regeneron Pharmaceuticals Inc: 2 directors
Two Directors at Regeneron Pharmaceuticals Inc sold after exercising options/sold 122,830 shares at between 974.303USD and 979.225USD. The significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary ...
More than $9 Million Awarded to High School Scientists and Engineers a...
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024 Grace Sun, 16, receives $75,000 Top Award for a new kind of organic electrochemical transistor at the world’s largest pre-college science, technology, engineering and math (STEM) competition. TARRYTOWN, N.Y. and WASHINGTON, D.C., May 17, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Grace Sun, 16, of Lexington, Kentucky, won the $75,000 top award, the George D. Yancopoulos Inno...
- Dave Nicoski
- Ross LaDuke
Vermilion Short Shots: Technically Vulnerable Stocks
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
TWI TITAN INTERNATIONAL INC.
TNET TRINET GROUP INC.
RYI RYERSON HOLDING CORPORATION
PZZA PAPA JOHN'S INTERNATIONAL INC.
PII POLARIS INC.
J7Z JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
JACK JACK IN THE BOX INC.
HURN HURON CONSULTING GROUP INC.
FIVE FIVE BELOW INC.
EXTR EXTREME NETWORKS INC.
EXPE EXPEDIA GROUP INC.
EXEL EXELIXIS INC.
EXAS EXACT SCIENCES CORPORATION
EVH EVOLENT HEALTH INC CLASS A
CLX CLOROX COMPANY
ACAD ACADIA PHARMACEUTICALS INC.
BF.B BROWN-FORMAN CORPORATION CLASS B
COHU COHU INC.
IONS IONIS PHARMACEUTICALS INC.
LEG LEGGETT & PLATT INCORPORATED
TAP MOLSON COORS BEVERAGE COMPANY CLASS B
THS TREEHOUSE FOODS INC.
WH WYNDHAM HOTELS & RESORTS INC.
BMY BRISTOL-MYERS SQUIBB CO. CEDEAR
SUZBY SUZANO SA
PGNY PROGYNY
ODP THE ODP CORPORATION
APA APA CORPORATION
PTLO PORTILLOS INC
STVN STEVANATO GRP SPA
FNA PARAGON 28 INC
SHLS SAKHALIN SHIPPING CO ORD
P RAILPOWER TECHNOLOGIES CORP COM
- Laura Chico
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investiga...
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis Development of BIIB105, an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS), will be discontinued based on data from the Phase 1/2 ALSpire studyBiogen and Ionis continue their long-standing commitment to developing therapies for ALS given the devastating impact of this progressive, fatal neurodegenerative condition CAMBRIDGE, Mass. and CARLSBAD, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Inc. (Nasdaq: BIIB) and (Nasdaq: IONS) announced the de...
- Laura Chico
EOG Resources Inc: 2 directors
Two Directors at EOG Resources Inc sold/sold after exercising options 18,776 shares at between 130.037USD and 130.305USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all...
Antero Resources Corp: 1 director
A director at Antero Resources Corp sold 50,000 shares at 33.720USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
Schlumberger Ltd: 1 director
A director at Schlumberger Ltd sold 63,095 shares at 48.260USD and the significance rating of the trade was 88/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
Eisai Initiates Rolling Biologics License Application to US FDA for LE...
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status TOKYO and CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai has initiated the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administra...
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatm...
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) If approved, Dupixent would be the first treatment in the U.S. indicated for adolescents aged 12-17 years with inadequately controlled CRSwNP, a condition driven in part by underlying type 2 inflammation that obstructs the sinuses and nasal passages and can lead to a loss of sense of smell Current treatment options for adolescents with CRSwNP leave many patients with uncontrolled disease and often result in the recurrence of nasal polyps TARRY...
- Laura Chico
Halliburton Co: 4 directors
Four Directors at Halliburton Co sold 77,766 shares at between 36.920USD and 37.000USD. The significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the ...
Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Lev...
Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks Preliminary data detailed in an ASGCT oral presentation include results for one of the youngest children in the world to receive a gene therapy for genetic deafness Ongoing Phase 1/2 CHORD trial is currently enrolling infants and children in the U.S., UK and Spain TARRYTOWN, N.Y., May 08, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the investigatio...
Devon Energy Corp: 1 director
A director at Devon Energy Corp sold 20,000 shares at 51.040USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Occidental Announces First Quarter 2024 Results
Occidental Announces First Quarter 2024 Results HOUSTON, May 07, 2024 (GLOBE NEWSWIRE) -- (NYSE: OXY) today announced its first quarter 2024 financial results. The earnings release and accompanying financial schedules can be accessed via the section of the company’s website, . The earnings release is also available on the U.S. Securities and Exchange Commission’s website at sec.gov. The company will hold a conference call to discuss the results on Wednesday, May 8, 2024, at 1 p.m. Eastern/12 p.m. Central. The conference call may be accessed by calling 1-866-871-6512 (international call...
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Marathon Oil Corporation and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 6 May 2024 in which Moody's reassessed the appropriateness of the ratings in the c...
SLB OneSubsea and Subsea7 Awarded Integrated Contract for OKEA’s North...
HOUSTON--(BUSINESS WIRE)-- Regulatory News: This press release features multimedia. View the full release here: SLB OneSubsea and Subsea7 are providing North Sea compliant equipment for the sustainable field development of OKEA’s Bestla Project (Photo: Business Wire) SLB (NYSE: SLB) has announced the award of a sizeable integrated engineering, procurement, construction, and installation (EPCI) contract by OKEA to its OneSubsea™ joint venture and Subsea7. The contract will see the partnership develop the Bestla (formerly known as Brasse) Project in the North Sea, offshore Norway, specifically ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.